Acquiring immune reconstitution after hematopoietic stem cell transplantation

Ifigeneia Tzannou and Ann M Leen

Viral infections remain a significant cause of morbidity and mortality after hematopoietic stem cell transplantation. Pharmacologic agents are effective against some pathogens, but they are costly and can be associated with significant toxicities. Thus, many groups have investigated adoptive T-cell transfer as a means of hastening immune reconstitution and preventing and treating viral infections. This review discusses the immunotherapeutic strategies that have been explored.

Keywords: adoptive immunotherapy; hematopoietic stem cell transplantation; T cells; viral infections

Allogeneic hematopoietic stem cell transplantation (HSCT) is increasingly applied as a curative treatment for a variety of both malignant and nonmalignant hematological diseases. However, the majority of patients requiring an allogeneic transplant do not have an available human leukocyte antigen (HLA)-identical sibling donor, necessitating the use of alternative stem cell sources including HLA-matched or -mismatched unrelated donors, haploidentical donors or cord blood units. The extension of HSCT to these higher-risk patients who either receive more extensively manipulated products (for example, T cell-depleted grafts) or require more intensive and prolonged post-transplant immunosuppression has resulted in a coincident rise in infection-related morbidity and mortality associated with a range of viruses including cytomegalovirus (CMV), Epstein–Barr virus (EBV), BK virus, human herpesvirus 6, influenza, parainfluenza, human metapneumovirus, adenovirus (AdV) and respiratory syncitial virus. Pharmacologic agents are effective against only some of these pathogens, but they are costly and can be associated with significant toxicities. In addition, as the use of antivirals does not accelerate immune reconstitution, infections frequently recur after treatment termination. This has led a number of groups to investigate whether adoptive T-cell transfer approaches might provide a safe and effective means of providing both immediate and long-term antiviral protection. Our review discusses some of the immunotherapeutic strategies that have been explored.

DONOR LYMPHOCYTE INFUSION (DLI)

The first adoptive transfer studies involved the infusion of unmanipulated donor lymphocytes containing a spectrum of T cells specific for all pathogens encountered by that donor over their lifetime. However, despite promising results, the adoptive transfer of unmanipulated T cells also carries with it the risk of causing graft-versus-host disease (GvHD), because of the high frequency of alloreactive cells present in the infused product. Furthermore, because of the low circulating frequency of T cells reactive against many common viruses including AdV, respiratory syncitial virus, parainfluenza and human metapneumovirus, higher DLI doses may be required to confer clinical benefit, further increasing the risk of GvHD.

ALLOREACTIVE T-CELL DEPLETION

In order to retain the activity but enhance the safety of DLIs, a number of groups have investigated strategies to selectively deplete or inactivate alloreactive T cells.

Selective alloredepletion ex vivo

One approach to safely accelerate immune reconstitution is to remove alloreactive T cells from the donor graft before infusion. To identify the alloreactive sub-population within the DLI product, donor lymphocytes are first co-cultured with recipient-derived antigen presenting cells (APCs), including peripheral blood mononuclear cells, keratinocytes, EBV-transformed B lymphoblastoid cell lines (EBV-LCL), dendritic cells (DCs) or fibroblasts. Activated T cells that proliferate and upregulate activation markers, including CD25, CD69, CD71, CD134, CD137 and HLA-DR, can subsequently be eliminated using immunomagnetic depletion, immunotoxin-conjugated antibody-based depletion, photodepletion or induction of apoptosis.

Van Dijk et al. were the first to demonstrate that the depletion of alloantigen-activated T cells is feasible. In their preclinical study, the investigators cultured donor T cells with patient keratinocytes in the presence of an anti-CD28 antibody, followed by incubation with...
microbeads conjugated to monoclonal antibodies directed to CD25, CD69, CD71 and HLA-DR, used individually or in combination. After selective depletion by immunomagnetic separation, they reported a 10-fold decrease in the frequency of T-cell precursors reactive against the same patient-derived APCs, whereas activity against third-party cells remained unchanged.\textsuperscript{19} Similar studies have been performed using a CD25 antibody coupled to the deglycosylated ricin A chain (dgA) (called RFT5-SMPT-dgA). Indeed, Montagna et al.\textsuperscript{18} demonstrated that after activation with haploidentical peripheral blood mononuclear cells, incubation with this antibody-conjugated immunotoxin efficiently depleted alloreactive T cells, whereas those with antiviral activity were retained. This preclinical study was translated to a clinical phase I/II trial in which 15 pediatric transplant patients, 13 of whom received haploidentical grafts, were administered alloseparated donor T cells at doses ranging from 1 to $8 \times 10^5$ cells per kg between days 15 and 47 post transplant. Even at the highest dose, the infusions proved safe, with only four patients developing acute GVHD (aGVHD; grade I/II) and one patient presenting with limited chronic GVHD (cGVHD). In addition, the alloseparated cells showed evidence of antiviral activity in vivo. Specifically, in three patients with active CMV and/or EBV reactivations unresponsive to antiviral drugs, infection-associated symptoms resolved post infusion.\textsuperscript{23} Solomon et al.\textsuperscript{29} applied this strategy in the adult setting for recipients of matched sibling donor HSCTs. They incubated donor peripheral blood mononuclear cells with ex vivo expanded recipient-derived T cells followed by alloepletion with RFT5-SMPT-dgA that produced a mean five fold decrease in host-reactive cells. Subsequently, on the day of transplant, a substantially larger dose of cells (median 1 to $10^6$ alloseparated T cells per kg) was administered to 16 elderly patients with advanced hematologic malignancies who were considered high risk for developing GVHD. Post infusion, 8 patients developed acute GVHD that was severe in 4 (2 grade III and 2 grade IV), and the severity of GVHD appeared to correlate with the efficiency of allosepletion.\textsuperscript{29} Finally, Amrolia et al.\textsuperscript{30} performed a phase I dose-finding clinical study using EBV-LCL-depleted donor T cells in the haploidentical setting for pediatric and adult patients with high-risk hematologic malignancies. Sixteen patients received 10⁴ to 10⁵ cells per kg that were administered on days 30, 60 and 90 post transplant. Two patients developed significant acute GVHD (1 patient at each dose tested) that evolved to extensive chronic GVHD in both cases and was lethal in one individual. Importantly, the only dose level of 10⁴ cells per kg supported immune reconstitution, and in this group rapid recovery of CMV- and EBV-specific immunity was observed as early as 2–4 months post HSCT.\textsuperscript{30}

Photodynamic purging has also been used to deplete alloreactive T cells. This platform was developed to overcome fluctuations in activation-based surface marker expression and to achieve a more consistent and effective alloepletion. The technique is based on the impaired ability of activated T cells to excrete a phototoxid rhodamine-like dye (TH9402) because of activation-induced changes in a multidrug-resistance P-glycoprotein. Consequentially, exposure of TH9402-exposed, alloactivated cells to visible light results in apoptosis.\textsuperscript{31} In a phase I clinical trial, Roy et al.\textsuperscript{32,33} prepared alloseparated cells using photodynamic purging that were administered on day 34 ± 6 at doses ranging from 1 x $10^4$ to 5 x $10^5$ cells per kg to 19 adults, all of whom had undergone T cell-depleted haploidentical HSCTs. The alloseparated cells caused acute GVHD (grade I/II) in 4 patients, but chronic GVHD developed in 9 patients, the majority of whom received the higher doses. Reconstitution of CD4^+ (helper) and CD8^+ (cytotoxic) T cells to ‘normal’ levels occurred more rapidly in patients administered the top cell dose and 67% of patients in this group remained infection free during the first 6 months post infusion in comparison with only 14% of patients who received the lowest cell dose.\textsuperscript{32,33} Given the apparent safety and antiviral protection conferred by the cell infusions, Mielke et al.\textsuperscript{24} performed a follow-up study in which 24 adults with hematological malignancies (16 high risk) received 5 x $10^6$ per kg selectively photodepleted donor T cells (from an HLA-matched sibling) on the day of transplant. The frequency of GVHD was relatively high, with a probability of acute GVHD grade II–IV of 38 ± 10% and 13 ± 7% for grade III–IV, whereas the probability of developing chronic GVHD was 65 ± 11%. However, serious viral, bacterial and fungal infections were common and persistent. Of the patients infused, 20 developed CMV reactivations that required treatment, 5 patients experienced viral-associated hemorraghic cystitis and 1 patient died of respiratory syncitial virus pneumonitis. Recurrent bacterial infections were detected in five patients, four of whom died, and four patients developed invasive fungal infections. Ultimately, the trial was prematurely terminated because of both unexpected duration and the severity of these infectious complications.\textsuperscript{34}

In vivo T-cell depletion

Alloreactive T cells can also be depleted in vivo by genetically engineering the infused cells to incorporate a ‘safety switch’ that can be triggered should adverse effects occur.\textsuperscript{35,36} Various suicide gene systems have been evaluated preclinically, including CD20 and rituximab,\textsuperscript{37} varicella zoster virus-derived thymidine kinase and the prodrug 6-Methoxypurine arabinoside,\textsuperscript{38} cytomegavirus deaminase and 5-Fluorocytosine,\textsuperscript{39} purine nucleoside phosphorylase and 6-methylpurine-2-deoxoriboiside,\textsuperscript{40} Carboxypeptidase A and Methotrexate-a-peptides.\textsuperscript{41} Two platforms have been tested clinically—herpes simplex viral thymidine kinase (HSV-tk) and inducible Caspase 9 (iC9). The HSV-tk gene functions by converting the prodrug ganciclovir to its active triphosphate form, leading to inhibition of DNA synthesis and death of dividing cells. In a phase I/II multicenter study, 28 haploidentical HSCT recipients received 0.9–40 x 10⁴ HSV-tk-modified donor lymphocytes per kg from day 28 post transplant. These infusions supported rapid (median 23 days post T cells) immune reconstitution, defined as circulating CD3^+ T-cell numbers of at least 100 cells per μl detected on two consecutive occasions in 22 patients, all of whom received ≥0.9 x 10⁶ cells per kg. In addition, these individuals had fewer and less severe infectious complications than those who did not reconstitute (infection-related mortality of 9% versus 60%). In this study, 10 patients developed acute (grade I–IV) GVHD between days 8 and 86 post infusion and 1 patient developed extensive chronic GVHD on day 146. In 1 patient with cutaneous grade I GVHD, the rash resolved spontaneously, but in the other 10 patients ganciclovir was administered, resulting in a significant reduction (40–93%) in the circulating frequency of HSV-tk-modified T cells and consequent complete clinical responses in all cases.\textsuperscript{42} However, there are several shortcomings associated with the use of HSV-tk as a suicide system that must also be taken into consideration, including the inherent immunogenicity of the virus-derived transgene that may lead to the premature elimination of the infused cells. In addition, its mechanism of action requires interference with DNA synthesis, and hence cell killing may be prolonged. Finally, the requirement for ganciclovir to activate the suicide gene removes the possibility of administering this agent as a treatment of viral infections post transplant.\textsuperscript{43,44} Nevertheless, the
activity of this approach is currently being tested in late-phase clinical studies.

An alternative suicide strategy is iC9, which is nonimmunogenic and triggered upon administration of a small-molecule dimerizer that produces apoptosis within 24 h, even in nondividing cells.\textsuperscript{45} The safety and activity of iC9-modified T cells was assessed in a phase I dose-escalation study where donor cell numbers ranging from 0.1 to 1 × 10\textsuperscript{8} cells per kg were infused to 5 haploidentical pediatric HSCT recipients at 30–90 days after transplantation. Four patients developed grade I/II GvHD and, following a single dose of the dimerizing drug AP1903, >90% of cells underwent apoptosis within 30 min, resulting in rapid resolution of GvHD (24–48 h) without recurrence. Importantly, virus-specific T cells (VSTs) were spared.\textsuperscript{46}

**Induction of anergy**

Functional inactivation rather than physical depletion of T cells has also been used as a means of protecting against GvHD. In order to become activated, T cells require ‘signal 1’ provided by T-cell receptor engagement with peptide presented in the context of HLA, as well as ‘signal 2’ provided by costimulatory molecules on T cells engaging their ligands on APCs. Of the latter, the interaction between CD28 and its ligands, B7-1 (CD80) and B7-2 (CD86), is one of the major positive costimulatory signals. This interaction can be specifically blocked using a fusion protein, for example CTLA4-Ig, that binds to B7 with higher affinity than CD28, or monoclonal antibodies to CD80 or CD86. In the event of stimulation with signal 1 in the absence of signal 2, cells enter a state of allospecific anergy.

This approach was tested clinically by Guinan et al.\textsuperscript{47} who reported the outcome of 12 patients aged 0.5–26 years who received alloenergized haploidential bone marrow grafts for high-risk hematologic malignancies. To induce alloantigen-specific anergy, bone marrow from the donor was cocultured with recipient lymphocytes in the presence of CTLA4-Ig, resulting in a decrease in alloreactive precursor T cells by a median of 4 logs. A median of 16 × 10\textsuperscript{8} CD3\textsuperscript{+} T cells per kg was infused on the day of HSCT and just 3 patients developed GvHD (grade II/III), but all resolved.\textsuperscript{47} In order to better assess the safety and effectiveness of this technique with respect to its ability to promote immune reconstitution and control infections, the same group performed two follow-up phase I trials. A total of 24 patients (pediatric and adult) with high-risk hematologic malignancies or bone marrow failure received haploidential stem cell grafts containing a median of 29 × 10\textsuperscript{8} CD3 per kg that had been alloenergized using CTLA4-Ig (n = 19) or anti-B7.1 and anti-B7.2 antibodies (n = 5). Despite the high T-cell dose infused, GvHD of ≥grade III was seen in only five patients. Moreover, both absolute lymphocyte and CD4\textsuperscript{+} T-cell recovery occurred within 3 months of infusion and there was evidence of virus-specific T-cell expansion in vivo. Indeed, in three evaluable patients with CMV reactivation, a rapid expansion of CD8\textsuperscript{+} T cells to levels exceeding those required for protection was observed.\textsuperscript{48}

An alternative approach to reduce GvHD in vivo is to infuse regulatory T cells (Tregs) that have the capacity to inhibit activated T cells. In a phase I clinical trial of this approach, 23 adults with advanced-stage hematologic malignancies received two cord blood units followed by 1 or 2 infusions of Tregs on days +1 and +15 (1–30 × 10\textsuperscript{8} and 30 × 10\textsuperscript{8} cells per kg, respectively). The incidence of aGvHD (grade III/IV) was 17% overall and 11% for those who received a Treg dose of ≥30 × 10\textsuperscript{8} per kg.\textsuperscript{49} Similarly, Di Ianni et al.\textsuperscript{50} administered Tregs (2 × 10\textsuperscript{8} or 4 × 10\textsuperscript{8} cells per kg) to 28 haploidential HSCT patients 4 days before transplant, at which point they also received a DLI (0.5 × 10\textsuperscript{8}, 1 × 10\textsuperscript{8} or 2 × 10\textsuperscript{8} per kg). Only 2 of 26 evaluable patients developed ≥grade II aGvHD, both of whom also received the highest doses of both Tregs and DLI. The Tregs did not inhibit immune reconstitution, with CD4 and CD8 counts reaching 50 per μl within 1 month after transplantation that reflected an expansion of T-cell populations directed against a range of pathogens including *Aspergillus fumigatus*, *Candida albicans*, CMV and AdV. Overall, fewer episodes of CMV reactivation occurred compared with those reported after haploidential HSCT, and no patient developed CMV disease.

**Adoptive transfer of VSTs**

The adoptive transfer of selected or ex vivo expanded VST populations has also been utilized to provide in vivo antiviral protection.

**RAPID ISOLATION STRATEGIES**

Several groups have focused on selection approaches that facilitate the isolation of VST populations directly from peripheral blood for immediate transfer to patients with acute infections. These include the isolation of HLA-peptide multimer-binding T cells or the selection of cytokine-producing T cells following a short (12–16 h) in vitro stimulation.

HLA-peptide multimers consist of individual peptide epitopes refolded with appropriate HLA class I molecules that can bind to epitope-specific CD8\textsuperscript{+} T cells and are subsequently selected for infusion using magnetic beads. Cobbold et al.\textsuperscript{51} used a panel of CMV IE1 and pp65 tetramers (a complex of 4 peptide-loaded HLA molecules) to select specific T cells from nine HSCT donors that were administered to 6 recipients of matched related and 3 recipients of matched unrelated transplants with CMV reactivations. Although only small doses (1.2 × 10\textsuperscript{3}–3.3 × 10\textsuperscript{8} cells per kg) of exclusively CD8\textsuperscript{+} T cells were infused, post transfer the cells were able to expand and persist in vivo, as indicated by their detection 100 days post infusion. In addition, clearance of CMV DNA was documented in eight of nine infused patients, with no case of CMV disease reported.\textsuperscript{51} Uhlin et al.\textsuperscript{52} used pentamers to select CD8\textsuperscript{+} T cells reactive against not only CMV (HLA B7, A2 and B35) but also EBV (HLA A2) and AdV (HLA A1) either from frozen DLI products or from the peripheral blood of haploidential relatives. These cells (0.8–24.6 × 10\textsuperscript{8} cells per kg) were infused to 6 patients with refractory CMV, 1 with EBV-PTLD and 1 with an AdV infection, and produced clinical responses with a reduction in viral titer documented in 6 of the 8 treated patients.\textsuperscript{52}

Despite the apparent clinical benefit associated with the adoptive transfer of multimer-selected cells, concerns have recently been raised regarding the impact that multimer binding may have on the activity of the selected T-cell populations. Indeed, Maile et al.\textsuperscript{53} demonstrated that prolonged HLA-peptide/T-cell receptor interaction can induce epitope-specific tolerance in a dose-dependent manner, resulting in clonal exhaustion/anergy of the multimer-bound T cells.\textsuperscript{53} To address this problem, Neudorfer et al.\textsuperscript{54,55} designed streptamers that have the binding properties of traditional multimers but can be rapidly dissociated from T cells by the addition of a competitor molecule, subsequently making the isolated population phenotypically and functionally indistinguishable from untreated T cells. In a recent clinical trial of this approach, Schmitt et al.\textsuperscript{56} administered a single infusion of selected CMV-directed CD8\textsuperscript{+} T cells to two allogeneic HSCT patients with CMV infections who were unresponsive to antiviral drugs. Patient 1 received a single infusion of 2.2 × 10\textsuperscript{8} HLA A24/pp65 cells per kg that resulted in an increase in the circulating frequency of CMV-specific T cells from 0 to 27.1% of all...
peripheral blood T cells. Similarly, in patient 2, who received only $3.5 \times 10^9$ HLA B7/pp65 cells per kg, there was an increase in the frequency of reactive cells from 0.03 to 0.48%. In both cases, the T-cell infusions resulted in CMV clearance without GvHD.\textsuperscript{56}

The second method (\(\gamma\)-capture) for rapid selection of virus-specific cells relies on the capacity of memory T cells to secrete interferon-\(\gamma\) (IFN\(\gamma\)) in an antigen-dependent manner. Feuchtinger et al.\textsuperscript{57} first used this method to select AdV-directed T cells for the treatment of systemic AdV infections in nine pediatric allograft recipients. Donor-derived AdV-reactive cells were activated by short-term (16 h) \textit{in vitro} stimulation using species C adenoviral antigen as a stimulus, followed by magnetic selection of the IFN\(\gamma\)-secreting population that contained both CD4\(^+\) (mean 63.2%) and CD8\(^+\) (mean 28.7%) T cells. The infusions were safe and despite the small numbers of cells infused (range 1.2–50 \times 10^3 per kg) 5 of 6 evaluable patients exhibited a substantial reduction in viral load in both peripheral blood and stool with a corresponding increase in the circulating frequency of AdV-specific T cells. This group later applied this strategy to treat chemorefractory CMV disease or reactivation (\(n=18\) children and adults who had received a T cell-depleted allo-HSCT), and in 83% of cases CMV was either eliminated or patients had a > 1 log viral load reduction, including 2 patients with CMV encephalitis.\textsuperscript{58} Peggs et al.\textsuperscript{59} also used IFN\(\gamma\)-captured CMV pp65-specific T cells as prophylaxis and preemptive treatment. In a phase I/II study, 18 patients received a median of 2840 CD4\(^+\) and 630 CD8\(^+\) CMV-specific T cells per kg early (median day 35) post transplant, and expansion of both cell subset populations was observed. However, aGvHD (grade I–III) occurred in eight patients and extensive cGvHD (mean 63.2%) T cells. The \(\gamma\)-captured EBNA1- and CD8\(^+\) T cells. Instead, IFN\(\gamma\)-secreting T cells in 2 patients, who demonstrated a clinical and virologic response, defined as a decrease in viral load of > 1 log and resolution of PTLD.\textsuperscript{61}

Thus, to date these direct selection approaches have proven safe and allow for the rapid preparation and infusion of virus-specific precursors. However, multimer selection requires the generation of HLA-specific reagents for each viral epitope and thus has been restricted to CD8\(^+\) T cells. Instead, IFN\(\gamma\) capture provides an HLA-unrestricted means of selecting both CD4\(^+\) and CD8\(^+\) memory T cells. However, both methods require large volumes of donor blood, and even then only small numbers of captured cells are obtained, so that only viruses with a high frequency of circulating T-cell precursors can be targeted.

### Table 1 Clinical trials using \textit{in vitro} expanded VSTs

| Stimulation                                      | Target   | Patients | Prophylaxis or treatment (number of patients) | Viral outcomes                                      | References       |
|-------------------------------------------------|----------|----------|-----------------------------------------------|-----------------------------------------------------|------------------|
| CMV-infected fibroblasts                        | CMV      | 14       | Prophylaxis                                    | No CMV infections                                    | Walter et al.\textsuperscript{62} |
| CMV lysate-stimulated PBMCs                     | CMV      | 8        | Treatment                                      | 6 CR, 1 PR, 1 NR                                    | Einsele et al.\textsuperscript{63} |
| CMV antigen-pulsed DCs                          | CMV      | 28       | Prophylaxis                                    | 23 Responded to VSTs with antivirals                 | Peggs et al.\textsuperscript{66} |
| pp65-pulsed or Ad5f35pp65 vector-transduced DCs | CMV      | 50       | Treatment                                      | 26 Patients developed CMV infections, 9 Required antivirals, 1 CMV-related death | Blyth et al.\textsuperscript{69} |
| EBV-LCLs                                        | EBV      | 118      | Prophylaxis (105) Treatment (13)               | No new EBV infections, 11 CR, 2 Deaths              | Rooney et al.\textsuperscript{70} |
| EBV-LCLs                                        | EBV      | 6        | Treatment                                      | 5 Displayed a decrease in viral load, 1 EBV-related death | Comoli et al.\textsuperscript{73} |
| EBV-LCLs                                        | EBV      | 3        | Treatment                                      | 3 CR, 13 CR                                        | Dubrovina et al.\textsuperscript{75} |
| Ad5f35pp65 vector-transduced EBV-LCLs and PBMCs | AdV, CMV | 11       | Prophylaxis (10) Treatment (1)                 | 3/3 CR of EBV infection/PTLD, 3/3 CR of CMV infection, 6/6 CR of AdV infection/disease | Leen et al.\textsuperscript{77} |
| Plasmid-nucleofected DCs                        | EBV, AdV, CMV | 10    | EBV treatment (4), AdV treatment (5), CMV treatment (5) | 3 CR, 5 CR, 4 CR, 1 patient with persistent colitis proceeded with colectomy | Gerdemann et al.\textsuperscript{82} |

Abbreviations: AdV, adenovirus; CMV, cytomegalovirus; CR, complete response; DC, dendritic cell; EBV, Epstein-Barr virus; EBV-LCL, EBV-transformed B lymphoblastoid cell line; NR, non-responder; PBMC, peripheral blood mononuclear cell; PR, partial response; PTLD, post-transplant lymphoproliferative disease; VST, virus-specific T cell.
ADOPTIVE TRANSFER OF EX VIVO EXPANDED VSTS

An alternative strategy to enhance immune recovery after HSCT is to infuse VSTS that have been selectively expanded ex vivo to enrich for pathogen-specific populations with a corresponding dilution in alloreactive cells. This approach has been implemented by a number of groups for the prevention and treatment of infections associated with CMV, EBV and AdV, which will be summarized in the following section (Table 1).

CMV

CMV is a latent β-herpesvirus that frequently reactivates in immuno-compromised allogeneic HSCT recipients in the absence of CMV-specific CD4\(^+\) and CD8\(^+\) T cells. Thus, a number of groups have investigated whether in vitro expanded VSTS generated using CMV-infected fibroblasts, peptide/antigen-loaded DCs or adenovector-transduced APCs could provide clinical benefit. Walter et al.\(^{62}\) were the first to test this approach clinically using CD8\(^+\) T-cell clones that had been activated and expanded using autologous fibroblasts infected with the AD169 strain of CMV. These cells were administered prophylactically to 14 recipients of HLA-matched transplants at weekly intervals in doses escalating from 3.3 \(\times 10^6\) to 1 \(\times 10^9\) per kg from day 30 post transplant. The infusions were safe, with only three patients developing de novo grade II/III GvHD, but all responded to steroid treatment. Before adoptive transfer, all 14 patients lacked CMV-specific T cells, but these became detectable by days 12 to 19 post infusion and persisted for at least 8 weeks after cessation of therapy, as indicated by T-cell receptor clonotyping studies. Consequently, none of the infused patients developed CMV reactivation or disease. However, the magnitude of clonotyping studies. Consequently, none of the infused patients developed CMV reactivation or disease. However, the magnitude of response, highlighting the importance of CD4\(^+\) T-cell help in sustaining antiviral activity.\(^{62}\)

In an effort to promote in vivo persistence, Einsele et al.\(^{63}\) prepared polyclonal CMV-specific T cells by incubating donor peripheral blood mononuclear cells with CMV lysate followed by restimulation with autologous irradiated feeder cells loaded with CMV antigen. After 4 stimulations, the product for infusion contained a mixture of CD4\(^+\) (mean 77 ± 10%) and CD8\(^+\) (mean 6 ± 3%) T cells that were CMV specific as measured by intracellular IFN\(\gamma\) staining, but lacked alloreactive cells as tested in a mixed lymphocyte culture. Eight recipients of matched or mismatched sibling or unrelated donor-derived EBV-specific T cells generated using EBV-LCL as a stimulus. In our initial study, 3 patients with EBV-PTLD and 7 high-risk patients received 0.4–1.8 \(\times 10^8\) cells per m\(^2\) with no adverse effects and complete viral elimination was achieved in all patients with active disease.\(^{70}\) We subsequently extended this study and infused a total of 39 high-risk allograft recipients with 2–4 infusions of EBV-specific T cells that established a dose of 2 \(\times 10^7\) cells per m\(^2\) as safe and effective. In 12 patients where immune reconstitution was measured, there was a median 32-fold increase in EBV-specific T-cell precursors 1 month post treatment, and 6 patients with elevated EBV-DNA levels at the time of infusion had a 2–4 log decrease in their viral load within 2 to 3 weeks of receiving cells.\(^{72}\) More recently, we have reviewed the long-term outcome of 114 patients, aged 0.5–38 years, who were infused with 2 \(\times 10^7\) per m\(^2\) EBV-specific T cells as prophylaxis (\(n = 101\)) or treatment (\(n = 13\)) for EBV-PTLD. The cells were effectively able to control PTLD in 80% of patients who received the cells therapeutically and were 100% effective in those who were prophylactically infused, in comparison with a PTLD incidence of 11.5% in controls. In the first 26 patients, the T-cell lines were genetically marked with a retroviral vector encoding the neomycin resistance gene that facilitated tracking studies and demonstrated that functional T cells persisted for up to 9 years.\(^{20}\)

These results have been reproduced by numerous centers,\(^{73,74}\) including the group from Memorial Sloan Kettering Cancer Center who infused 19 patients with biopsy-proven EBV-PTLD with EBV-LCL-activated T cells. The patients received 3 weekly doses of 10\(^6\) cells per kg that proved safe and induced a complete response in 13 (68%) patients. Interestingly, in 3 patients who failed to respond to T-cell therapy, the investigators demonstrated that the infused T-cell lines, expanded using EBV B95-8-transformed B cells as APCs, failed to recognize patient-derived infected B cells, implying antigenic differences between the EBV B95-8 laboratory strain and the endogenous virus responsible for the PTLD. Furthermore, in two recipients of haploidentical or HLA-mismatched grafts, the infused donor-derived T-cell lines were found to selectively recognize EBV peptides presented in the context of non-shared HLA alleles, facilitating tumor immune escape.\(^{75}\) Our group reported a similar outcome associated with the infusion of a line that failed to recognize an endogenous virus deletion mutant.\(^{76}\) These reports highlight the importance of manufacturing and infusing polyclonal T-cell lines that ideally recognize multiple CD8\(^+\) and CD4\(^+\) T-cell epitopes from multiple antigens and have been confirmed to recognize recipient-derived targets via a shared HLA allele.

Epstein–Barr virus

EBV has also proven amenable to VST therapy. Our group first targeted EBV reactivations post transplant with in vitro expanded donor-derived EBV-specific T cells generated using EBV-LCL as a stimulus. In our initial study, 3 patients with EBV-PTLD and 7 high-risk patients received 0.4–1.8 \(\times 10^8\) cells per m\(^2\) with no adverse effects and complete viral elimination was achieved in all patients with active disease.\(^{70}\) We subsequently extended this study and infused a total of 39 high-risk allograft recipients with 2–4 infusions of EBV-specific T cells that established a dose of 2 \(\times 10^7\) cells per m\(^2\) as safe and effective. In 12 patients where immune reconstitution was measured, there was a median 32-fold increase in EBV-specific T-cell precursors 1 month post treatment, and 6 patients with elevated EBV-DNA levels at the time of infusion had a 2–4 log decrease in their viral load within 2 to 3 weeks of receiving cells.\(^{72}\) More recently, we have reviewed the long-term outcome of 114 patients, aged 0.5–38 years, who were infused with 2 \(\times 10^7\) per m\(^2\) EBV-specific T cells as prophylaxis (\(n = 101\)) or treatment (\(n = 13\)) for EBV-PTLD. The cells were effectively able to control PTLD in 80% of patients who received the cells therapeutically and were 100% effective in those who were prophylactically infused, in comparison with a PTLD incidence of 11.5% in controls. In the first 26 patients, the T-cell lines were genetically marked with a retroviral vector encoding the neomycin resistance gene that facilitated tracking studies and demonstrated that functional T cells persisted for up to 9 years.\(^{20}\)

These results have been reproduced by numerous centers,\(^{73,74}\) including the group from Memorial Sloan Kettering Cancer Center who infused 19 patients with biopsy-proven EBV-PTLD with EBV-LCL-activated T cells. The patients received 3 weekly doses of 10\(^6\) cells per kg that proved safe and induced a complete response in 13 (68%) patients. Interestingly, in 3 patients who failed to respond to T-cell therapy, the investigators demonstrated that the infused T-cell lines, expanded using EBV B95-8-transformed B cells as APCs, failed to recognize patient-derived infected B cells, implying antigenic differences between the EBV B95-8 laboratory strain and the endogenous virus responsible for the PTLD. Furthermore, in two recipients of haploidentical or HLA-mismatched grafts, the infused donor-derived T-cell lines were found to selectively recognize EBV peptides presented in the context of non-shared HLA alleles, facilitating tumor immune escape.\(^{75}\) Our group reported a similar outcome associated with the infusion of a line that failed to recognize an endogenous virus deletion mutant.\(^{76}\) These reports highlight the importance of manufacturing and infusing polyclonal T-cell lines that ideally recognize multiple CD8\(^+\) and CD4\(^+\) T-cell epitopes from multiple antigens and have been confirmed to recognize recipient-derived targets via a shared HLA allele.

Multipathogen-directed VSTS

In order to broaden the specificity of viruses that could be targeted by a single T-cell line, we subsequently developed a strategy to simultaneously activate and expand T cells reactive against CMV, AdV and EBV using, as APCs, monocytes and EBV-LCLs transduced...
with an adenoviral vector encoding the immunodominant CMV pp65 antigen. Although it was feasible to generate these trivirus VSTs, in general the lines were dominated by the CMV-reactive component. Nevertheless, when small doses (ranging from $5 \times 10^6$ to $1.5 \times 10^6$ cells per m$^2$) were infused to 11 recipients of haploidentical, HLA-matched related or unrelated donor transplants, the cells proved safe and effective against all 3 viruses in vivo.\textsuperscript{77,78}

### SIMPLIFYING VST PRODUCTION

Although the administration of ex vivo expanded donor-derived VSTs has proven to be safe and effective in the post-HSCT setting, broader implementation is limited by the logistics of manufacture and the requirement for individualized products. For example, for the production of trivirus-directed T-cell lines, the generation of the EBV-LCLs alone requires 4–6 weeks. Subsequently, VSTs are activated and expanded using monocytes and EBV-LCLs transduced with the adenopp65 vector, resulting in an additional 4–6 weeks of culture. The infectious virus (EBV B95-8) and clinical grade adenoviral vector required for VST generation are expensive to make and test, whereas the prolonged period of culture (8–12 weeks for VST manufacture and 1–2 weeks for product release testing) is lengthy and complex, necessitating the speculative manufacture of VSTs for all at-risk subjects without guarantee of their eventual need. Fortunately, it has now become possible to address many of the manufacturing issues enabling cost-effective and rapid VST production using simplified technologies that should facilitate the introduction of the approach into broader clinical practice (Figure 1).

#### Reducing manufacturing time

To eliminate the requirement for live virus/viral vectors, we have investigated alternative antigen sources including DNA plasmids encoding a range of immunodominant and subdominant viral antigens from EBV, CMV and AdV as T-cell stimulants. These plasmids were introduced into DCs using the AMAXA nucleofection system (Lonza, Inc., Allendale, NJ, USA) and resulted in efficient VST generation in just 17 days.\textsuperscript{78} More recently, we have also evaluated the direct stimulation of donor peripheral blood mononuclear cells with clinically available peptide mixture (pepmixes) as an approach to rapidly expand antigen-specific populations. These pepmixes consist of 15-mer peptides overlapping by 11 amino acids spanning immunogenic target antigens. As each peptide is 15 amino acids in length, pepmixes covered the majority of both CD8$^+$ and CD4$^+$ epitopes\textsuperscript{79} and produced VSTs that were phenotypically and functionally equivalent to conventionally generated T-cell lines, thus eliminating the requirement for DCs or other specialized APCs. Thus, by incorporating pepmixes as a stimulus, the manufacturing time is reduced to just 10 days.\textsuperscript{80}

#### Reducing complexity

Traditionally, VSTs have been generated using standard tissue-culture treated 24-well plates, with weekly T-cell stimulation and frequent manipulation (counting, splitting and feeding). Thus, the process is laborious and time consuming, limiting scalability. To address this issue, our group, in collaboration with Wilson Wolf Manufacturing, has developed and tested a gas-permeable culture device (G-Rex) with a silicone membrane at the base that allows for efficient O$_2$ and CO$_2$ exchange. Incorporation of this silicone membrane thus allows for the initial input media volume to be increased which in turn, increases the available nutrients and dilutes waste products with minimal cell handling required. These optimized growth conditions increase output by up to 20-fold (from $2–3 \times 10^6$ per cm$^2$ in traditional plastic ware to $\sim 10^7$ cells per cm$^2$ in the G-Rex).\textsuperscript{81}

#### Reducing antigenic competition

Until recently, the maximum number of viruses that have been targeted by a single line has been limited to three because repetitive in vitro stimulation of T-cell cultures leads to antigenic competition within our cultures. For example, our trivirus (EBV$^+$ + CMV$^+$ + AdV$^+$)-specific products were dominated by CMV-specific T cells at the expense of the AdV- and EBV-specific components. This antigenic competition and the resultant production of lines with restricted viral specificities limits their clinical value. To overcome this limitation and retain both high- and low-frequency T cells, we supplemented our cultures with different Th1 (T helper type 1) polarizing and prosurvival cytokines (including interleukin (IL)-15, IL2 and a combination of IL4 and IL7) that have been reported to prevent activation-induced cell death, and found that the combination of IL4 and IL7 supported the expansion and survival of both CD4$^+$ and CD8$^+$ virus-specific T cells that recognized multiple viral epitopes and killed virus-infected targets. The induced cells were Th1 polarized and lacked alloreactive T cells, even when the VSTs had been produced by only a single in vitro stimulation with pepmixes. By implementing this change, we were able to mitigate the impact of antigenic competition, allowing us to incorporate additional specificities within our VSTs.\textsuperscript{82,83}

#### Clinical trials using rapidly generated VSTs

To test the safety and clinical activity of rapidly generated VSTs, we first performed a phase I clinical trial using trivirus (AdV, EBV, CMV)-directed VSTs that had been activated using plasmid-nucleofected DCs as APCs and expanded for 9–11 days in a G-Rex device in media supplemented with IL4 and IL7. Ten patients with reactivations of one or more viruses received cell infusions ranging from 0.5 to $2 \times 10^7$ VSTs per m$^2$ between day 27 and month 52 post HSCT. The infusions were safe, with only one patient developing a mild and localized skin rash post infusion. In addition, the cells produced clinical benefit and complete virological responses in 8 of 10 patients treated for active infections associated with one or more of the targeted viruses.\textsuperscript{84} We are currently testing the activity of pepmix-stimulated VSTs directed against EBV, AdV, CMV, human herpesvirus 6 and BK virus (clinicaltrials.gov)\textsuperscript{85} (Figure 1).

#### EXTENDING THE APPLICABILITY OF VSTs

The range of viruses that can be treated, the avoidance of biohazardous agents such as live viruses and the accelerated manufacture should facilitate broader introduction of VST-based approaches for intractable virus infection in the immunocompromised host. However, the individualized nature of the products for infusion as well as the requirement for seropositive donors preclude extending the strategy to recipients of grafts from seronegative donors. Two approaches may overcome these barriers.

#### VST generation from seronegative donors

The activation and expansion of VSTs from seronegative donors and cord blood (CB) remains challenging because of both the naive phenotype of the T cell and their low circulating precursor frequency. Hence, the generation of VSTs in vitro requires the use of professional APCs (for example, DCs) as well as potent activating/Th1-polarizing cytokines including IL12, IL15 and IL7. In preclinical studies, Park et al.\textsuperscript{86} were the first to demonstrate the feasibility of activating and expanding CMV-directed VSTs from CB, whereas more recently...
Hanley et al.\textsuperscript{85} have generated trivirus-directed T cells targeting AdV, EBV and CMV using the 20% fraction of the CB graft. They have clinically translated their approach and, to date, 7 transplant recipients have been infused with these CB-derived cells at doses ranging from 0.5 to 2.5$\times$10\textsuperscript{9} cells per m\textsuperscript{2} on days 63–146 post transplant, with no infusion-related toxicities or subsequent GvHD. Two of these patients had evidence of viral reactivation; the first with both AdV and CMV, and the second patient had an EBV reactivation. In both cases, the viruses were controlled, although for CMV two infusions were required.\textsuperscript{86} Hence, it appears that adoptively transferred CB VSTs can support immune reconstitution, although whether such cells will have the same \textit{in vivo} persistence and antiviral activity as VSTs generated from seropositive donors remains to be seen.

Third-party VST banks
An alternate approach to more broadly implement VST-based therapies involves the use of banked T-cell lines that have been prepared in advance from seropositive individuals with common HLA polymorphisms. These cells can be administered in the partially HLA-matched third-party setting as an ‘off the shelf’ product available for immediate use. However, one must consider the potential for inducing GvHD with these often substantially HLA-mismatched products. Nevertheless, a number of studies have demonstrated the feasibility, safety and clinical benefit associated with this therapy. For example, Haque \textit{et al.}\textsuperscript{87,88} prepared a bank of EBV-specific T cells that were used to treat patients with EBV-PTLD after solid organ ($n = 31$) or stem cell ($n = 2$) transplant. In their initial study, lines for infusion were selected based on the best HLA-A, B and DR match and were administered in 4 weekly doses of 2$\times$10\textsuperscript{6} VSTs per kg. Overall, the infusions proved safe with no acute toxicity, GvHD or adverse effects on the transplanted organ. At 5 weeks and 6 months after the first infusion, the complete or partial response rates were 65 and 52%, respectively. Responses were associated with the number, but not the loci of HLA matches, that ranged from 2/6 to 5/6 HLA, and the level of overall HLA match correlated with a significantly better response to T-cell therapy at 6 months.\textsuperscript{87,88} Similarly, the Memorial Sloan Kettering group reported that third-party EBV-specific T cells produced complete responses in four of five patients with EBV PTLD after HSCT (including two cord blood transplant recipients).\textsuperscript{75,89} Finally, in a recent multicenter study, our group administered partially HLA-matched trivirus-directed VSTs to 50...
allogeneic HSCT recipients with refractory EBV, CMV and AdV infections. From a bank of just 32 lines, we were able to identify a product for 90% of patients screened for study participation, and selection of lines for infusion was based on the specificity of the line for the target virus through a shared HLA allele as well as the overall level of HLA match. Eighteen VST lines were administered as treatment for persistent CMV (n = 23), AdV (n = 18) and refractory EBV-PTLD (n = 9). The infusions were well tolerated, and even though the lines infused matched at 1 to 4 of the recipients’ HLA antigens, de novo GVHD occurred in only 2 patients, grade I in both cases. Overall, the infusions were associated with clinical benefit as 74% of treated patients had a complete or partial response—74%, 79% and 67% for CMV, AdV and EBV, respectively, that was durable in the majority of cases. ELISPOT assays performed on pre- and post-infusion follow-up samples demonstrated an increase in the frequency of virus-reactive cells in ∼50% of responders. In addition, in vivo T-cell persistence, monitored using deep sequencing analysis, indicated that donor-derived T-cell receptor sequences persisted for 4–12 weeks post infusion, though our expectation is that as endogenous host immunity recovered the infused cells were eliminated. As the data from three centers support both the safety and efficacy of banked VSTs, it should be possible to use this approach as a means of more broadly implementing VST therapy.

FUTURE PERSPECTIVES

Evidence from over 20 years of adoptive VST and selected T-cell transfer studies overwhelmingly supports the safety and clinical benefit associated with this therapeutic modality as a means to prevent and treat viral infections and support endogenous immune reconstitution. However, there is still limited access to this therapy for most HSCT patients. The ability to simultaneously protect against multiple viruses using a broad-spectrum VST product is more cost effective and less toxic that the alternative of administering multiple therapies of life threatening adenoviral infections after T-cell-depleted bone marrow transplantation. Blood 1994; 84, 1699–1690.

Couriel D, Canas J, Engler H, Collins A, Dunbar C, Barrett AJ. Early reactivation of cytomegalovirus and high risk of interstitial pneumonitis following T-depleted BMT for adults with hematological malignancies. Bone Marrow Transplant 1996; 18, 347–353.

Or R, Hadar E, Bitan M, Resnick IB, Aker M, Ackerstein A et al. Safety and efficacy of donor lymphocyte infusions following mismatched stem cell transplantation. Biol Blood Marrow Transplant 2006; 12, 1299–1301.

Montagna D, Yoon R, Calcetara V, Comoli P, Locatelli F, Maccario R et al. Depletion of alloreactive T cells by a specific anti-interleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral activity. Blood 1999; 93, 3550–3557.

Van Dijk AM, Kessler FL, Stadhouders-Keef SA, Verdonck LF, de Gast GC, Otten HG. Selective depletion of major and minor histocompatibility antigen reactive T cells: towards prevention of acute graft versus-host disease. Br J Haem 1999; 107, 169–175.

Heslop HE. Slobod KS, Pule MA, Donnelly JA, Smith CA et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Biol Blood Marrow Transplant 2010; 16, 925–935.

Amrolia P, Mucciozzi-Casadei G, Yoon E, Huls H, Sili U, Wieder ED et al. Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood 2003; 102, 2292–2299.

Albon SJ, Manders AL, Sirmo K, White G, Rice K, Brewin J. Practical approach to selective allodepletion. Transplantation 2007; 83, 1341–1347.

Thomson R, Tellez-Velasco S, van der Burg L, Conlon AN, van der Lelie I et al. Selective and effective depletion of donor alloreactive T cells by a novel CD3/CD57 targeted immunotoxin: a phase I/II study. Cancer Immunol Immunother 2011; 60, 1303–1311.

Khan S, Todorova M, Link I, Thies J et al. Depletion of alloreactive T lymphocytes using patient-derived nonhematopoietic stromal cells in allograft engineering. Transplantation 2008; 86, 1427–1435.

Solomon SR, Mielke S, Savani BN, Montero A, Wisch L, Childs R et al. Selective depletion of alloreactive donor T lymphocytes via CD69: implications on antiviral, antileukemic and immunoregulatory function. Bone Marrow Transplant 2010; 45, 297–305.

Ge X, Brown J, Sykes M, Bosuissinis VA. CD134-allodepletion allows selective elimination of alloreactive human T cells without loss of virus-specific and leukemia-specific effectors. Biol Blood Marrow Transplant 2008; 14, 518–530.

Maurudais DA, Yang Y, Hensel N, Lewalle P, Couriel D, Kreitman RJ et al. Specific depletion of alloreactivity against haplotype mismatched related individuals by a recombinant immunotoxin: a new approach to graft-versus-host disease prophylaxis in haploidentical bone marrow transplantation. Bone Marrow Transplant 1996; 17, 793–799.

Sathar,S. Ortega SB, Mundy DI, Collins RH, Karandikar NJ. In vitro methotrexate as a practical approach to selective allodepletion. Biol Blood Marrow Transplant 2007; 13, 644–645.

Norton N, Herr W, Khan S, Todorova M, Link I, Thies J et al. Selective depletion of alloreactive T lymphocytes using patient-derived nonhematopoietic stromal cell stimulators in haploidentical bone marrow transplantation. Bone Marrow Transplant 2005; 35, 1211–1219.

Amrolia P, Mucciozzi-Casadei G, Huls H, Adams S, Durell A, Gao A et al. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood 2006; 108, 1797–1808.

Mielke S, Nunes R, Rezvani K, Fellowes VS, Venne A, Solomon SR et al. A clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and matched related donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH94022-based photodepletion technique. Blood 2008; 111, 4392–4402.

Roy DC, Lachance S, Kiss T, Cohen S, Busque L, Fish D et al. Haploidentical stem cell transplantation: high doses of alloreactive T-cell depleted donor lymphocytes
administered post-transplantation decreases infections and improve survival without causing severe GvHD. Blood 2009;114(abstract 512).

33 Roy DC, Guerin M, Boumedine RS, Lachance S, Cohen S, Sauvageau G et al. Reduction in incidence of severe infections by transplantation of high doses of allogeneic peripheral T cells selectively depleted of alloreactive units. Blood 2011;118(abstract 3020).

34 Mielke S, Micolzer V, Shenyu A, Fellows V, Khuu H, Stroncek DF et al. Selectively T cell depleted allografts from HLA-matched sibling donors followed by low-dose post transplantation immunosuppression to improve transplant outcome in patients with hematological malignancies. Biol Blood Marrow Transplant 2011; 17, 1855–1861.

35 Munshi NC, Gaviria-Granjan L, Drake R, Ding LM, Iyer R, Saylor R et al. Thymidine kinase (TK) gene transduced human lymphocytes can be highly purified, remain fully functional, and are killed efficiently with ganciclovir. Blood 1997; 89, 1334–1340.

36 Markel S, Magnani Z, Ciceri F, Cazaniga S, Riddell SR, Travessier C et al. Immunologic potential of donor lymphocytes expressing a suicide gene for early immune restoration after hematopoietic T-cell-depleted stem cell transplantation. Blood 2003; 101, 1290–1298.

37 Vogler I, Newzela S, Hartmann S, Schneider N, von Laer D, Koehl U et al. Improved bicistronic CD20/tCD34 vector for efficient purification and in vivo depletion of modified CD19+ cells for adoptive immunotherapy. Mol Ther 2010; 18, 1330–1338.

38 Huber BE, Richards CA, Kreintskiy TA. Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy. Proc Natl Acad Sci USA 1991; 88, 8039–8043.

39 Kucerova L, Aftanaro V, Matsukova M, Tyciakova S, Aftanaro C. Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy. Cancer Res 2007; 67, 6304–6313.

40 Zhou JH, Tang B, Liu XL, He DW, Yang DT. HTERT-targeted E. coli purine nucleoside phosphorylase gene-knockout cells sensitize tumor cells to methotrexate-alpha-peptide prodrugs. Blood 1999; 93, 2164–2171.

41 Hamstra DA, Page M, Maybaum J, Rehmulata A. Expression of endogenously activated secreted or cell surface carboxypeptidase A sensitizes tumor cells to methotrexate-alpha-peptide prodrugs. Cancer Res 2000; 60, 657–665.

42 Ciceri F, Bonci C, Stanghellini MT, Bondanza A, Traversari C, Salomoni M et al. In vivo injection of suicide gene-engineered donor lymphocytes after high-dose allogeneic hematopoietic stem-cell transplantation for leukemia (the TK007 trial): a non-randomised phase-I study. Lancet Oncol 2009; 10, 489–500.

43 Ridderstrale E, Elwig EJ, Fischbach J, Lehmann VA, Gyllenberg S, Wiltz L, Manley SA et al. Cell-mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med 1996; 2, 216–223.

44 Tiberghien P, Faroni C, Lioure B, Milpied N, Angonin R, Deconinck E et al. T cell depletion allografts from HLA-matched sibling donors followed by low-dose immunosuppression to prevent alloreactivity. Blood 2003; 101, 1375–1382.

45 Peggs K, Verfuhrt S, Pizzey A, Khan N, Guiver M, Moss PA et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with an autologous cytomegalovirus-specific T-cell line. Lancet 2005; 365, 891–896.

46 Peggs K, Verfuhrt S, Pizzey A, Chow SL, Thomson K, Mackinnon S et al. Cytomegalovirus-specific T cell immunotherapy promotes restoration of durable functional antiviral immunity following allogeneic stem cell transplantation. Clin Infect Dis 2009; 49, 1851–1860.

47 Mickelthwate K, Hansen A, Foster A, Snape E, Antonovas V, Sartor M et al. In vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation. Blood 2008; 112, 3974–3981.

48 Feuchtinger T, Matthes-Martin S, Richard C, Lion T, Fuhrer M, Hamprecht K et al. Induction of cytomegalovirus (CMV)-specific T cells in mice immune to CMV infection not responding to antiviral chemotherapy. Blood 2002; 99, 3916–3922.

49 Peggs K, Verfuhrt S, Mackinnon S. Induction of cytomegalovirus (CMV)-specific T-cell responses using dendritic cells engineered with CMV antigen: a novel culture system free of live CMV virions. Blood 2001; 97, 994–1000.

50 Peggs K, Verfuhrt S, Pizzey A, Khan N, Guiver M, Moosmann A et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. New Eng J Med 1995; 333, 1038–1044.

51 Brunstein CG, Miller JS, Cao Q, McKenna DH, Hippen KL, Curtsinger J et al. Outcome of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: Preemptive therapy for viruses in the immunocompromised host. Blood 2005; 106, 2232–2241.

52 Steinberg PD, Ferrand C, Lioure B, Milpied N, Angonin R, Deconinck E et al. Administration of herpes simplexthymidine kinase-expressing donor T cells with a cytomegalovirus (CMV) gene-transduced human lymphocytes can be highly purified, remain fully functional, and are killed efficiently with ganciclovir. Blood 1997; 89, 1334–1340.

53 Tey SK, Dotti G, Rooney CM, Heaslop HE, Brenner MK. Inducible caspase 9 suicide gene therapy for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002; 99, 3916–3922.

54 Ciceri F, Bonci C, Stanghellini MT, Bondanza A, Traversari C, Salomoni M et al. In vivo injection of suicide gene-engineered donor lymphocytes after high-dose allogeneic hematopoietic stem-cell transplantation for leukemia (the TK007 trial): a non-randomised phase-I study. Lancet Oncol 2009; 10, 489–500.

55 Tey SK, Dotti G, Rooney CM, Heaslop HE, Brenner MK. Inducible caspase 9 suicide gene therapy for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002; 99, 3916–3922.

56 Peggs K, Verfuhrt S, Pizzey A, Khan N, Guiver M, Moosmann A et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. New Eng J Med 1995; 333, 1038–1044.

57 Mickelthwate K, Clancy L, Sandher U, Hansen AM, Blth E, Antonovas V et al. Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5SIP565 gene-modified dendritic cells after allogeneic hematopoietic stem cell transplantation. Blood 2008; 112, 3974–3981.

58 Tey SK, Dotti G, Rooney CM, Heaslop HE, Brenner MK. Inducible caspase 9 suicide gene therapy for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002; 99, 3916–3922.

59 Ciceri F, Bonci C, Stanghellini MT, Bondanza A, Traversari C, Salomoni M et al. In vivo injection of suicide gene-engineered donor lymphocytes after high-dose allogeneic hematopoietic stem-cell transplantation for leukemia (the TK007 trial): a non-randomised phase-I study. Lancet Oncol 2009; 10, 489–500.

60 Tey SK, Dotti G, Rooney CM, Heaslop HE, Brenner MK. Inducible caspase 9 suicide gene therapy for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002; 99, 3916–3922.

61 Ciceri F, Bonci C, Stanghellini MT, Bondanza A, Traversari C, Salomoni M et al. In vivo injection of suicide gene-engineered donor lymphocytes after high-dose allogeneic hematopoietic stem-cell transplantation for leukemia (the TK007 trial): a non-randomised phase-I study. Lancet Oncol 2009; 10, 489–500.

62 Tey SK, Dotti G, Rooney CM, Heaslop HE, Brenner MK. Inducible caspase 9 suicide gene therapy for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002; 99, 3916–3922.

63 Tey SK, Dotti G, Rooney CM, Heaslop HE, Brenner MK. Inducible caspase 9 suicide gene therapy for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002; 99, 3916–3922.

64 Tey SK, Dotti G, Rooney CM, Heaslop HE, Brenner MK. Inducible caspase 9 suicide gene therapy for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002; 99, 3916–3922.

65 Ciceri F, Bonci C, Stanghellini MT, Bondanza A, Traversari C, Salomoni M et al. In vivo injection of suicide gene-engineered donor lymphocytes after high-dose allogeneic hematopoietic stem-cell transplantation for leukemia (the TK007 trial): a non-randomised phase-I study. Lancet Oncol 2009; 10, 489–500.
81 Vera JF, Brenner LJ, Gerdemann U, Ngo MC, Sili U, Liu H et al. Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). *J Immunother* 2010; 33, 305–315.

82 Gerdemann U, Katari UL, Papadopoulou A, Keirnan JM, Craddock JA, Liu H, Martinez CA et al. Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. *Mol Ther* 2013; 11, 2113–2121.

83 Papadopoulou A, Katari U, Gerdemann U, Martinez C, Leung K, Carrum G et al. Safety and clinical efficacy of rapidly-generated virus-specific T cells with activity against Adv, EBV, CMV, HHV6 and BK virus administered after allogeneic hematopoietic stem cell transplant. *Blood* 2013; 122 (abstract 148).

84 Park KO, Marti L, Kurtzberg J, Szabolcs P. In vitro priming and expansion of cytomegalovirus specific Th1 and Tc1 T cells from naive cord blood lymphocytes. *Blood* 2006; 108, 1770–1773.

85 Hanley PJ, Cruz CR, Savoldo B, Leen AM, Stanojevic M, Khalil M et al. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. *Blood* 2009; 114, 1958–1967.

86 Hanley PJ, Martinez C, Leung K, Savoldo B, Dotti G, Brenner MK, Rooney CM et al. Improving immune reconstitution after cord blood transplantation using ex vivo expanded virus-specific T cells: a phase I clinical study. *Blood* 2012; 120 (abstract 224).

87 Haque T, Wilkie GM, Taylor C, Amlot P, Murad P, Iley A et al. Treatment of Epstein-Barr virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. *Lancet* 2002; 360, 436–442.

88 Haque T, Wilkie GM, Jones MM, Higgins CD, Urquhart G, Wingate P et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. *Blood* 2007; 110, 1123–1131.

89 Barker JN, Dzubrovina E, Sauter C, Jaroscak JJ, Perales MA, Dzubrovin M et al. Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes. *Blood* 2010; 116, 5045–5049.

90 Leen AM, Bollard CM, Mendizabal AM, Sipaul EJ, Szabolcs P, Antin JH et al. Multicenter study of banked third party virus-specific T-cells to treat severe viral infections after hematopoietic stem cell transplantation. *Blood* 2013; 121, 5113–5123.